{"id":35432,"date":"2025-10-01T08:19:33","date_gmt":"2025-10-01T08:19:33","guid":{"rendered":"https:\/\/www.hotelsalepage.com\/feed\/cision-pr-newswire\/telix-announces-record-breaking-presence-at-eanm-2025\/"},"modified":"2025-10-01T08:19:33","modified_gmt":"2025-10-01T08:19:33","slug":"telix-announces-record-breaking-presence-at-eanm-2025-2","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=35432","title":{"rendered":"Telix Announces Record-Breaking Presence at EANM 2025"},"content":{"rendered":"<table border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/1920208\/Telix_Main_Logo_Logo.jpg?p=medium600\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\" \/><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">MELBOURNE, Australia<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Sept. 30, 2025<\/span><\/span> \/PRNewswire\/ &#8212; Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, &#8220;Telix&#8221;) today announces its record-breaking conference presence with 28 company-related abstract presentations at the 38<sup>th<\/sup> Annual Congress of the European Association of Nuclear Medicine (EANM) to be held in <span class=\"xn-location\">Barcelona<\/span> from 4 \u2013 <span class=\"xn-chron\">8 October 2025<\/span>.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\">\n<\/div>\n<p>Dr. <span class=\"xn-person\">David N. Cade<\/span>, Telix Group Chief Medical Officer, said, &#8220;We are pleased to showcase our late-stage and next generation development programs and innovations in MedTech at EANM \u2013 the largest gathering of nuclear medicine professionals worldwide. Telix presentation highlights include the Phase 3 ProstACT Global trial of TLX591 in mCRPC<sup>[1]<\/sup>, the IPAX-Linz and IPAX-2 therapeutic trials of TLX101 in glioma, and real-world experience with TLX250-CDx in ccRCC<sup>[2]<\/sup>. Telix will host a sponsored symposium on CAIX<sup>[3]<\/sup> and FAP<sup>[4]<\/sup> targeting theranostics, and abstracts will also be presented from Telix&#8217;s pan-tumor programs and its Rhine Pharma subsidiary, whose mission is to expand global access to innovative cancer imaging and therapy.&#8221;<\/p>\n<p>As in previous years, Telix will again support the EANM Sanjiv Sam Gambhir Young Investigator Award, in memory of an extraordinary man and an inspiring educator.<\/p>\n<p>Visit booth #78 to explore opportunities for collaboration with Illuccix\u00ae\u00a0(kit for the preparation of gallium-68 gozetotide injection) Telix&#8217;s commercial PSMA-PET<sup>[5]<\/sup> imaging agent in <span class=\"xn-location\">Europe<\/span>, our industry-leading theranostic pipeline and medical technologies, including the SENSEI\u00ae miniature drop-in gamma probe, QDOSE\u00ae dosimetry software and artificial intelligence (AI).<\/p>\n<p><b>EANM presentation details are as follows (all times CEST):<\/b>\u00a0<\/p>\n<p><b><u>Sponsored Symposium<\/u><\/b><\/p>\n<p><b>Title: <\/b><i>From pan-tumor innovation to theranostic precision<\/i><i>. Fibroblast activation protein (FAP) and carbonic anhydrase IX (CAIX) case studies<br \/><\/i><b>Date &amp; Time: <\/b>5-Oct-25, 13:15 \u2013 14:45<br \/><b>Location: <\/b>Room 116, CCI Barcelona<br \/><b>Chair:<\/b> A. Italiano, Institut Bergoni\u00e9 (University of <span class=\"xn-location\">Bordeaux<\/span>) &amp; <span class=\"xn-person\">Gustave Roussy<\/span> (Villejuif), <span class=\"xn-location\">France<\/span><br \/><b>Agenda:<br \/><\/b><i>Agnostic approaches in oncology and drug development: setting the stage<\/i><\/p>\n<ul type=\"disc\">\n<li>A.\u00a0Italiano<\/li>\n<\/ul>\n<p><i>Introduction to FAP and diagnostic applications<\/i><\/p>\n<ul type=\"disc\">\n<li>Y.\u00a0Mori, Department of Nuclear Medicine, Medical Faculty and University Hospital <span class=\"xn-location\">Duesseldorf, Germany<\/span><\/li>\n<\/ul>\n<p><i>FAP-targeted Radiopharmaceutical Therapy: A Promising Avenue in Radiomolecular Oncology<\/i><\/p>\n<ul type=\"disc\">\n<li>R.\u00a0Baum, CURANOSTICUM Wiesbaden-Frankfurt MVZ, Center for Advanced Radiomolecular Precision Oncology, DKD HELIOS Klinik, Wiesbaden, <span class=\"xn-location\">Germany<\/span><\/li>\n<\/ul>\n<p><i>Clinical Applications of CAIX<\/i><\/p>\n<ul type=\"disc\">\n<li>D.\u00a0Oprea-Lager, Department of Medical Imaging, Radboud University Medical Center, Nijmegen, <span class=\"xn-location\">the Netherlands<\/span><\/li>\n<\/ul>\n<p><i>Therapeutic potential of CAIX inhibitors<\/i><\/p>\n<ul type=\"disc\">\n<li>C.\u00a0Su\u00e1rez, Vall d&#8217;Hebron University Hospital, <span class=\"xn-location\">Barcelona, Spain<\/span><\/li>\n<\/ul>\n<p><b><u>Oral presentations<\/u><\/b><\/p>\n<p><b>Title:<\/b>\u00a0Investigating FAP binding of the dimeric DOTAGA.Glu.(FAPI)<sub>2<\/sub> (TLX400) labelled with terbium-161 in ovarian cancer models incorporating the tumor microenvironment<sup>[6]<br \/><\/sup><b>Date and Time:<\/b> 5-Oct-25, 15:10\u00a0 \u2013 15:20<br \/><b>Presenter: <\/b>I. Primac, SCK CEN, Mol, <span class=\"xn-location\">Belgium<\/span><br \/><b>Abstract #: <\/b>OP-150<\/p>\n<p><b>Title:<\/b> Reactive evaluation &#8211; a novel alternative to transfer learning to handle multi-centric variations in prostate cancer cohorts<br \/><b>Date and Time:<\/b> 6-Oct-25, 09:45 \u2013 09:55<br \/><b>Presenter: <\/b>L. Papp, Medical University of <span class=\"xn-location\">Vienna<\/span>, <span class=\"xn-location\">Vienna, Austria<\/span><br \/><b>Abstract #: <\/b>OP-352<\/p>\n<p><b>Title:<\/b>\u00a0Tumor-stroma dynamics define FAP optimum imaging and therapeutic windows in the management of glioblastoma<br \/><b>Date and Time:<\/b> 6-Oct-25, 16:00 \u2013 16:10<br \/><b>Presenter: <\/b>A. Bilinska, Bern University Hospital, <span class=\"xn-location\">Bern, Switzerland<\/span><br \/><b>Abstract #: <\/b>OP-417<\/p>\n<p><b>Title:<\/b>\u00a0Synergistic anti-tumor effects of <sup>225<\/sup>Ac-DOTA-girentuximab (TLX252) combined with DNA damage response inhibitors in CAIX-positive renal cancer<br \/><b>Date and Time:<\/b> 7-Oct-25, 08:10 \u2013 08:20<br \/><b>Presenter: <\/b>Z. Cao, Olivia Newton-John Cancer Research Institute and Austin Health, Heidelberg, <span class=\"xn-location\">Australia<\/span><br \/><b>Abstract #: <\/b>OP-516<\/p>\n<p><b>Title:<\/b> Integration of spatial analysis and deep learning for enhanced tumor classification in total-body PET\/CT imaging: a preliminary study<br \/><b>Date and Time:<\/b> 7-Oct-25, 08:50 \u2013 09:00<br \/><b>Presenter: <\/b>D. Han, Telix Pharmaceuticals, <span class=\"xn-location\">Sydney, Australia<\/span><br \/><b>Abstract #: <\/b>OP-529<\/p>\n<p><b>Title:<\/b>\u00a0Combining CAIX-targeted radionuclide therapy with immune checkpoint inhibitors: which inhibitor and when?<br \/><b>Date and Time:<\/b> 7-Oct-25, 09:00 \u2013 09:10<br \/><b>Presenter: <\/b>S. Kleinendorst, RadboudUMC, Nijmegen, <span class=\"xn-location\">Netherlands<\/span><br \/><b>Abstract #: <\/b>OP-521<\/p>\n<p><b>Title:<\/b>\u00a0ProstACT Global: A Phase 3 study of lutetium (Lu177) rosopatamab tetraxetan (TLX591) plus standard of care vs standard of care alone in patients with metastatic castration-resistant prostate cancer<br \/><b>Date and Time:<\/b> 7-Oct-25, 15:40 \u2013 15:50<br \/><b>Presenter: <\/b>J. Piulats, Bellvitge Biomedical Research Institute, <span class=\"xn-location\">Barcelona, Spain<\/span><br \/><b>Abstract #: <\/b>OP-674<\/p>\n<p><b>Title:<\/b>\u00a0Preliminary assessment of <sup>89<\/sup>Zr-Girentuximab (TLX250-CDx) excretion and radiation protection in ccRCC patients undergoing PET\/CT imaging<br \/><b>Date and Time:<\/b> 7-Oct-25, 17:35 \u2013 17:45<br \/><b>Presenter: <\/b>A. Piai, IRCCS Ospedale San Raffaele, <span class=\"xn-location\">Milan, Italy<\/span><br \/><b>Abstract #: <\/b>OP-706<\/p>\n<p><b>Title:<\/b>\u00a0IPAX-Linz: Phase 2 study to evaluate safety, tolerability, and preliminary efficacy of carrier-added <sup>131<\/sup>I-IPA (TLX101) in patients with recurrent GBM concomitantly to 2nd line re-irradiation<br \/><b>Date and Time:<\/b> 8-Oct-25, 08:00 \u2013 08:10<br \/><b>Presenter: <\/b>J. Pichler, Kepler University Hospital, Linz, <span class=\"xn-location\">Austria<\/span><br \/><b>Abstract #: <\/b>OP-778<\/p>\n<p><b>Title:<\/b>\u00a0Safety of radioligand therapy with <sup>177<\/sup>Lu-FAPi-Dimer (TLX400) with dose escalation in a clinical setting<sup>6<br \/><\/sup><b>Date and Time:<\/b> 8-Oct-25, 08:10 \u2013 08:20<br \/><b>Presenter: <\/b>J. <span class=\"xn-person\">Urena Poch<\/span>, Rostock University Medical Center, Rostock, <span class=\"xn-location\">Germany<\/span><br \/><b>Abstract #: <\/b>OP-779<\/p>\n<p><b>Title:<\/b>\u00a0Immunomodulation of the tumor microenvironment by <sup>225<\/sup>Ac-DOTA-girentuximab (TLX252) in a syngeneic murine tumor mode<br \/><b>Date and Time:<\/b> 8-Oct-25, 09:10 \u2013 09:20<br \/><b>Presenter: <\/b>R. Ladjohounlou, <span class=\"xn-org\">University of Wisconsin, Madison<\/span>, WI, U.S.<br \/><b>Abstract #: <\/b>OP-767<\/p>\n<p><b><u>Poster presentations<\/u><\/b><\/p>\n<p><b>Title:<\/b>\u00a0Preclinical development of <sup>161<\/sup>Tb-DOTA-HYNIC-panPSMA and comparison with <sup>177<\/sup>Lu-DOTA-HYNIC-panPSMA, <sup>161<\/sup>Tb-DOTA-J591 and <sup>177<\/sup>Lu-DOTA-J591 (TLX591)<br \/><b>Presenter: <\/b>C. Morgat, CHU Bordeaux, <span class=\"xn-location\">Bordeaux, France<\/span><br \/><b>Abstract #: <\/b>EP-0069<\/p>\n<p><b>Title:<\/b>\u00a0CAIX-targeting for radioimmunotherapy in triple-negative breast cancer<br \/><b>Presenter: <\/b>A. Ivashkevich, Telix Pharmaceuticals, <span class=\"xn-location\">Melbourne, Australia<\/span><br \/><b>Abstract #: <\/b>EP-0130<\/p>\n<p><b>Title:<\/b>\u00a0Prostate cancer detection with <sup><span class=\"xn-money\">99m<\/span><\/sup>Tc-HYNIC-iPSMA SPECT: The Australian experience<br \/><b>Presenter: <\/b>P. Tually, Spartan First Imaging, Kalgoorlie, <span class=\"xn-location\">Australia<\/span><br \/><b>Abstract #: <\/b>EP-0353<\/p>\n<p><b>Title:<\/b>\u00a0Potential of <sup>89<\/sup>Zr-girentuximab (TLX250-CDx) PET\/CT for the routine clinical management of patients with suspicious, unspecified renal lesions (real-world experience)<br \/><b>Presenter: <\/b>S. Rasul, Medical University of <span class=\"xn-location\">Vienna<\/span>, <span class=\"xn-location\">Vienna, Austria<\/span><br \/><b>Abstract #: <\/b>EP-0528<\/p>\n<p><b>Title:<\/b>\u00a0Improving clinical management of von Hippel-Lindau Syndrome with <sup>89<\/sup>Zr-girentuximab (TLX250-CDx) PET Imaging (real-world experience)<br \/><b>Presenter: <\/b>F. Gelardi, IRCCS Ospedale San Raffaele, <span class=\"xn-location\">Milan, Italy<\/span><br \/><b>Abstract #: <\/b>EP-0534<\/p>\n<p><b>Title:<\/b>\u00a0IPAX-2: Phase 1 safety and dose finding study of <sup>131<\/sup>I-IPA (TLX101) plus standard of care in patients with newly diagnosed glioblastoma<br \/><b>Presenter: <\/b>J. Pichler, Kepler University Hospital, Linz, <span class=\"xn-location\">Austria<\/span><br \/><b>Abstract #: <\/b>EP-0785<\/p>\n<p><b>Title:<\/b>\u00a0<sup>177<\/sup>Lu-DOTA-HYNIC-panPSMA radioligand therapy for patients with metastatic castration-resistant prostate cancer<br \/><b>Presenter: <\/b>Y. Omar, Misr Radiology Center, <span class=\"xn-location\">Cairo, Egypt<\/span><br \/><b>Abstract #: <\/b>EP-0810<\/p>\n<p><b>Title:<\/b>\u00a0Robust self-supervised deep learning reconstruction model for reduced <sup>89<\/sup>Zr-girentuximab (TLX250-CDx) PET scan time<br \/><b>Presenter: <\/b>C. Pain, Monash Biomedical Imaging, <span class=\"xn-location\">Melbourne, Australia<\/span><br \/><b>Abstract #: <\/b>EP-0978<\/p>\n<p><b>Title: <\/b>Preclinical evaluation of DOTAGA.PEG<sub>2<\/sub>.Glu.(FAPI)<sub>2<\/sub>, a FAP dimeric inhibitor, for developing theranostic radiotracers in FAP-positive malignancies<sup>6<br \/><\/sup><b>Presenter:<\/b> N. Kumar,\u00a0Bern University Hospital, <span class=\"xn-location\">Bern, Switzerland<\/span><br \/><b>Abstract #: <\/b>EPS-013<\/p>\n<p><b>Title:<\/b>\u00a0Intraindividual tumor dosimetry of monomer <sup>90<\/sup>Y-FAPI-46 vs dimer <sup>90<\/sup>Y-DOTAGA-Glu-(FAPI)<sub>2<\/sub> FAP radioligand therapy of advanced stage solid tumors<br \/><b>Presenter: <\/b>P. <span class=\"xn-person\">Fragoso Costa<\/span>, University Hospital Essen, University Duisburg-Essen, <span class=\"xn-location\">Essen, Germany<\/span><br \/><b>Abstract #: <\/b>EPS-190<\/p>\n<p><b>Title:<\/b>\u00a0Therapeutic potential of DOTAGA.Glu.(FAPI)<sub>2<\/sub> (TLX400) and DO3A.Glu.(FAPI)<sub>2<\/sub> with human dosimetry extrapolation for 177-lutetium and 161-terbium<sup>6<br \/><\/sup><b>Presenter: <\/b>A. Bilinska, Bern University Hospital, <span class=\"xn-location\">Bern, Switzerland<\/span><br \/><b>Abstract #: <\/b>EPS-193<\/p>\n<p><b><u>Rhine Pharma presentations<\/u><\/b><\/p>\n<p><b>Title:<\/b>\u00a0Impact of formulation buffers on the radiolysis and stability of RHN001-Tx (<sup>188<\/sup>Re-PSMA)<br \/><b>Date and Time:<\/b> 6-Oct-25, 10:45 \u2013 10:55<br \/><b>Presenter: <\/b>S. Mdanda, Nuclear Medicine Research Infrastructure (NuMeRI), <span class=\"xn-location\">Pretoria, South Africa<\/span> <br \/><b>Abstract #: <\/b>OP-349<\/p>\n<p><b>Title:<\/b>\u00a0Clinical trial protocol for RHINO trial: Prospective single-center Phase 1\/2 study of RHN001-Dx\/Tx in men with PSMA-positive prostate cancer post adjuvant androgen deprivation therapy and\/or taxane-based chemotherapy<br \/><b>Date and Time:<\/b> 8-Oct-25, 09:20 \u2013 09:30<br \/><b>Presenter: <\/b>H. Ndlovu, NuMeRI, <span class=\"xn-location\">Pretoria, South Africa<\/span> <br \/><b>Abstract #: <\/b>OP-825<\/p>\n<p><b>Title:<\/b>\u00a0A comparative analysis of normal organ biodistribution and tumor uptake pattern of novel RHN001-Dx (<sup><span class=\"xn-money\">99m<\/span><\/sup>Tc-PSMA) in correlation with tumor burden and its implications for theranostic use<br \/><b>Date and Time:<\/b> 8-Oct-25, 11:05 \u2013 11:15<br \/><b>Presenter: <\/b>S. Martlbauer, University Hospital Dusseldorf, Heinrich-Heine-University Dusseldorf, <span class=\"xn-location\">Dusseldorf, Germany<\/span><br \/><b>Abstract #: <\/b>OP-881<\/p>\n<p><b>Title:<\/b>\u00a0A calibration workflow for accurate quantification of rhenium-188 in RHN001-Tx for theranostic applications<br \/><b>Presenter: <\/b>M. Qebetu, NuMeRI, <span class=\"xn-location\">Pretoria, South Africa<\/span><br \/><b>Abstract #: <\/b>EP-0942<\/p>\n<p><b>Title:<\/b>\u00a0Quantitative <sup><span class=\"xn-money\">99m<\/span><\/sup>Tc-SPECT\/CT dosimetry using a CZT gamma camera: Initial clinical experience<br \/><b>Presenter: <\/b>K. Ramonaheng, NuMeRI, <span class=\"xn-location\">Pretoria, South Africa<\/span> <br \/><b>Abstract #: <\/b>EP-1116<\/p>\n<p><b>Title:<\/b>\u00a0Production optimization and quality control testing of RHN001-Tx (<sup>188<\/sup>Re-PSMA) per GMP standards<br \/><b>Presenter: <\/b>S. Sibiya, NuMeRI, <span class=\"xn-location\">Pretoria, South Africa<\/span> <br \/><b>Abstract #: <\/b>EP-1200<\/p>\n<div>\n<table border=\"0\" cellspacing=\"0\" cellpadding=\"1\" class=\"prnbcc\">\n<tbody>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">[1] Metastatic castration-resistant prostate cancer.<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">[2]\u00a0Clear cell renal cell carcinoma.<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">[3]\u00a0Carbonic anhydrase IX.<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">[4]\u00a0Fibroblast activation protein.<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">[5]\u00a0Imaging of prostate specific membrane antigen.<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">[6]\u00a0Presentation includes information about a Telix-owned or licensed FAP-targeting theranostic candidate without input or support from Telix.<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n<p>\u00a0<\/p>\n<p><b>About <\/b><b>Rhine Pharma<\/b><\/p>\n<p>Rhine Pharma\u2122 is a wholly-owned subsidiary of Telix. Its mission is to expand global access to innovative cancer imaging and therapy by leveraging the unique benefits of technetium-99m (<sup><span class=\"xn-money\">99m<\/span><\/sup>Tc) and rhenium-188 (<sup>188<\/sup>Re).\u00a0 Visit <a href=\"http:\/\/www.rhine-pharma.com\/\" target=\"_blank\" rel=\"nofollow\">www.rhine-pharma.com<\/a>\u00a0for further information.<\/p>\n<p><b>About <\/b><b>Telix Pharmaceuticals Limited <\/b><\/p>\n<p>Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in <span class=\"xn-location\">Melbourne, Australia<\/span>, with international operations in <span class=\"xn-location\">the United States<\/span>, <span class=\"xn-location\">United Kingdom<\/span>, <span class=\"xn-location\">Brazil<\/span>, <span class=\"xn-location\">Canada<\/span>, <span class=\"xn-location\">Europe<\/span> (<span class=\"xn-location\">Belgium<\/span> and <span class=\"xn-location\">Switzerland<\/span>), and <span class=\"xn-location\">Japan<\/span>. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).<\/p>\n<p>Illuccix\u00ae (kit for the preparation of gallium-68 (<sup>68<\/sup>Ga) gozetotide injection), Telix&#8217;s first generation PSMA-PET imaging agent, has been approved in multiple markets globally. Gozellix\u00ae (kit for the preparation of gallium-68 (<sup>68<\/sup>Ga) gozetotide injection) has been approved by the U.S. Food and Drug Administration (FDA). Telix&#8217;s osteomyelitis (bone infection) imaging agent, technetium-99m (<sup><span class=\"xn-money\">99m<\/span><\/sup>Tc) besilesomab, marketed under the brand name Scintimun\u00ae, is approved in 32 European countries and <span class=\"xn-location\">Mexico<\/span>. Telix&#8217;s SENSEI\u00ae drop-in gamma probe is registered with the Australian Therapeutic Goods Administration (TGA) and with the FDA and has attained a Conformit\u00e9 Europ\u00e9enne (CE) Mark for use in the European Economic Area. Telix&#8217;s QDOSE\u00ae dosimetry software has received 510(k) clearance from the FDA and is CE-marked and Medical Device Regulation (MDR) certified for clinical use within the European Union (EU). No other Telix product has received a marketing authorization in any jurisdiction.<\/p>\n<p>Visit <a href=\"http:\/\/www.telixpharma.com\/\" target=\"_blank\" rel=\"nofollow\">www.telixpharma.com<\/a> for further information about Telix, including details of the latest share price, announcements made to the ASX, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on <a href=\"https:\/\/x.com\/TelixPharma\" target=\"_blank\" rel=\"nofollow\">X<\/a>\u00a0and\u00a0<a href=\"https:\/\/www.linkedin.com\/company\/telixpharma\/\" target=\"_blank\" rel=\"nofollow\">LinkedIn<\/a>.<\/p>\n<p><b>Telix Investor Relations<\/b><\/p>\n<p>Ms. Kyahn Williamson<br \/>Telix Pharmaceuticals Limited<br \/>SVP Investor Relations and Corporate Communications<br \/>Email: <a href=\"mailto:kyahn.williamson@telixpharma.com\" target=\"_blank\" rel=\"nofollow\">kyahn.williamson@telixpharma.com<\/a><\/p>\n<p><b>Legal Notices<\/b>\u00a0<\/p>\n<p>Cautionary Statement Regarding Forward-Looking Statements\u00a0\u00a0<\/p>\n<p><i>You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.\u00a0<\/i>\u00a0<\/p>\n<p><i>The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including <span class=\"xn-location\">the United States<\/span>. The information and opinions contained in this announcement are subject to change without notification. \u202fTo the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.\u00a0<\/i>\u00a0<\/p>\n<p><i>This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as &#8220;may&#8221;, &#8220;expect&#8221;, &#8220;intend&#8221;, &#8220;plan&#8221;, &#8220;estimate&#8221;, &#8220;anticipate&#8221;, &#8220;believe&#8221;, &#8220;outlook&#8221;, &#8220;forecast&#8221; and &#8220;guidance&#8221;, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix&#8217;s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix&#8217;s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix&#8217;s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix&#8217;s preclinical and clinical trials, and Telix&#8217;s research and development programs; Telix&#8217;s ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix&#8217;s product candidates, manufacturing activities and product marketing activities; Telix&#8217;s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix&#8217;s product candidates, if or when they have been approved; Telix&#8217;s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix&#8217;s expenses, future revenues and capital requirements; Telix&#8217;s financial performance; developments relating to Telix&#8217;s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix&#8217;s business; and the pricing and reimbursement of Telix&#8217;s product candidates, if and after they have been approved. Telix&#8217;s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.\u00a0<\/i>\u00a0<\/p>\n<p>Trademarks and Trade Names<\/p>\n<p><i>All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the \u00ae or \u2122 symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.\u00a0<\/i>\u00a0<\/p>\n<p><i>\u00a92025 Telix Pharmaceuticals Limited. All rights reserved.<\/i><\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<table border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/1920208\/Telix_Main_Logo_Logo.jpg?p=medium600\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\" \/><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">MELBOURNE, Australia<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Sept. 30, 2025<\/span><\/span> \/PRNewswire\/ &#8212; Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, &#8220;Telix&#8221;) today announces its record-breaking conference presence with 28 company-related abstract presentations at the 38<sup>th<\/sup> Annual Congress of the European Association of Nuclear Medicine (EANM) to be held in <span class=\"xn-location\">Barcelona<\/span> from 4 \u2013 <span class=\"xn-chron\">8 October 2025<\/span>.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\">\n<\/div>\n<p>Dr. <span class=\"xn-person\">David N. Cade<\/span>, Telix Group Chief Medical Officer, said, &#8220;We are pleased to showcase our late-stage and next generation development programs and innovations in MedTech at EANM \u2013 the largest gathering of nuclear medicine professionals worldwide. Telix presentation highlights include the Phase 3 ProstACT Global trial of TLX591 in mCRPC<sup>[1]<\/sup>, the IPAX-Linz and IPAX-2 therapeutic trials of TLX101 in glioma, and real-world experience with TLX250-CDx in ccRCC<sup>[2]<\/sup>. Telix will host a sponsored symposium on CAIX<sup>[3]<\/sup> and FAP<sup>[4]<\/sup> targeting theranostics, and abstracts will also be presented from Telix&#8217;s pan-tumor programs and its Rhine Pharma subsidiary, whose mission is to expand global access to innovative cancer imaging and therapy.&#8221;<\/p>\n<p>As in previous years, Telix will again support the EANM Sanjiv Sam Gambhir Young Investigator Award, in memory of an extraordinary man and an inspiring educator.<\/p>\n<p>Visit booth #78 to explore opportunities for collaboration with Illuccix\u00ae\u00a0(kit for the preparation of gallium-68 gozetotide injection) Telix&#8217;s commercial PSMA-PET<sup>[5]<\/sup> imaging agent in <span class=\"xn-location\">Europe<\/span>, our industry-leading theranostic pipeline and medical technologies, including the SENSEI\u00ae miniature drop-in gamma probe, QDOSE\u00ae dosimetry software and artificial intelligence (AI).<\/p>\n<p><b>EANM presentation details are as follows (all times CEST):<\/b>\u00a0<\/p>\n<p><b><u>Sponsored Symposium<\/u><\/b><\/p>\n<p><b>Title: <\/b><i>From pan-tumor innovation to theranostic precision<\/i><i>. Fibroblast activation protein (FAP) and carbonic anhydrase IX (CAIX) case studies<br \/><\/i><b>Date &amp; Time: <\/b>5-Oct-25, 13:15 \u2013 14:45<br \/><b>Location: <\/b>Room 116, CCI Barcelona<br \/><b>Chair:<\/b> A. Italiano, Institut Bergoni\u00e9 (University of <span class=\"xn-location\">Bordeaux<\/span>) &amp; <span class=\"xn-person\">Gustave Roussy<\/span> (Villejuif), <span class=\"xn-location\">France<\/span><br \/><b>Agenda:<br \/><\/b><i>Agnostic approaches in oncology and drug development: setting the stage<\/i><\/p>\n<ul type=\"disc\">\n<li>A.\u00a0Italiano<\/li>\n<\/ul>\n<p><i>Introduction to FAP and diagnostic applications<\/i><\/p>\n<ul type=\"disc\">\n<li>Y.\u00a0Mori, Department of Nuclear Medicine, Medical Faculty and University Hospital <span class=\"xn-location\">Duesseldorf, Germany<\/span><\/li>\n<\/ul>\n<p><i>FAP-targeted Radiopharmaceutical Therapy: A Promising Avenue in Radiomolecular Oncology<\/i><\/p>\n<ul type=\"disc\">\n<li>R.\u00a0Baum, CURANOSTICUM Wiesbaden-Frankfurt MVZ, Center for Advanced Radiomolecular Precision Oncology, DKD HELIOS Klinik, Wiesbaden, <span class=\"xn-location\">Germany<\/span><\/li>\n<\/ul>\n<p><i>Clinical Applications of CAIX<\/i><\/p>\n<ul type=\"disc\">\n<li>D.\u00a0Oprea-Lager, Department of Medical Imaging, Radboud University Medical Center, Nijmegen, <span class=\"xn-location\">the Netherlands<\/span><\/li>\n<\/ul>\n<p><i>Therapeutic potential of CAIX inhibitors<\/i><\/p>\n<ul type=\"disc\">\n<li>C.\u00a0Su\u00e1rez, Vall d&#8217;Hebron University Hospital, <span class=\"xn-location\">Barcelona, Spain<\/span><\/li>\n<\/ul>\n<p><b><u>Oral presentations<\/u><\/b><\/p>\n<p><b>Title:<\/b>\u00a0Investigating FAP binding of the dimeric DOTAGA.Glu.(FAPI)<sub>2<\/sub> (TLX400) labelled with terbium-161 in ovarian cancer models incorporating the tumor microenvironment<sup>[6]<br \/><\/sup><b>Date and Time:<\/b> 5-Oct-25, 15:10\u00a0 \u2013 15:20<br \/><b>Presenter: <\/b>I. Primac, SCK CEN, Mol, <span class=\"xn-location\">Belgium<\/span><br \/><b>Abstract #: <\/b>OP-150<\/p>\n<p><b>Title:<\/b> Reactive evaluation &#8211; a novel alternative to transfer learning to handle multi-centric variations in prostate cancer cohorts<br \/><b>Date and Time:<\/b> 6-Oct-25, 09:45 \u2013 09:55<br \/><b>Presenter: <\/b>L. Papp, Medical University of <span class=\"xn-location\">Vienna<\/span>, <span class=\"xn-location\">Vienna, Austria<\/span><br \/><b>Abstract #: <\/b>OP-352<\/p>\n<p><b>Title:<\/b>\u00a0Tumor-stroma dynamics define FAP optimum imaging and therapeutic windows in the management of glioblastoma<br \/><b>Date and Time:<\/b> 6-Oct-25, 16:00 \u2013 16:10<br \/><b>Presenter: <\/b>A. Bilinska, Bern University Hospital, <span class=\"xn-location\">Bern, Switzerland<\/span><br \/><b>Abstract #: <\/b>OP-417<\/p>\n<p><b>Title:<\/b>\u00a0Synergistic anti-tumor effects of <sup>225<\/sup>Ac-DOTA-girentuximab (TLX252) combined with DNA damage response inhibitors in CAIX-positive renal cancer<br \/><b>Date and Time:<\/b> 7-Oct-25, 08:10 \u2013 08:20<br \/><b>Presenter: <\/b>Z. Cao, Olivia Newton-John Cancer Research Institute and Austin Health, Heidelberg, <span class=\"xn-location\">Australia<\/span><br \/><b>Abstract #: <\/b>OP-516<\/p>\n<p><b>Title:<\/b> Integration of spatial analysis and deep learning for enhanced tumor classification in total-body PET\/CT imaging: a preliminary study<br \/><b>Date and Time:<\/b> 7-Oct-25, 08:50 \u2013 09:00<br \/><b>Presenter: <\/b>D. Han, Telix Pharmaceuticals, <span class=\"xn-location\">Sydney, Australia<\/span><br \/><b>Abstract #: <\/b>OP-529<\/p>\n<p><b>Title:<\/b>\u00a0Combining CAIX-targeted radionuclide therapy with immune checkpoint inhibitors: which inhibitor and when?<br \/><b>Date and Time:<\/b> 7-Oct-25, 09:00 \u2013 09:10<br \/><b>Presenter: <\/b>S. Kleinendorst, RadboudUMC, Nijmegen, <span class=\"xn-location\">Netherlands<\/span><br \/><b>Abstract #: <\/b>OP-521<\/p>\n<p><b>Title:<\/b>\u00a0ProstACT Global: A Phase 3 study of lutetium (Lu177) rosopatamab tetraxetan (TLX591) plus standard of care vs standard of care alone in patients with metastatic castration-resistant prostate cancer<br \/><b>Date and Time:<\/b> 7-Oct-25, 15:40 \u2013 15:50<br \/><b>Presenter: <\/b>J. Piulats, Bellvitge Biomedical Research Institute, <span class=\"xn-location\">Barcelona, Spain<\/span><br \/><b>Abstract #: <\/b>OP-674<\/p>\n<p><b>Title:<\/b>\u00a0Preliminary assessment of <sup>89<\/sup>Zr-Girentuximab (TLX250-CDx) excretion and radiation protection in ccRCC patients undergoing PET\/CT imaging<br \/><b>Date and Time:<\/b> 7-Oct-25, 17:35 \u2013 17:45<br \/><b>Presenter: <\/b>A. Piai, IRCCS Ospedale San Raffaele, <span class=\"xn-location\">Milan, Italy<\/span><br \/><b>Abstract #: <\/b>OP-706<\/p>\n<p><b>Title:<\/b>\u00a0IPAX-Linz: Phase 2 study to evaluate safety, tolerability, and preliminary efficacy of carrier-added <sup>131<\/sup>I-IPA (TLX101) in patients with recurrent GBM concomitantly to 2nd line re-irradiation<br \/><b>Date and Time:<\/b> 8-Oct-25, 08:00 \u2013 08:10<br \/><b>Presenter: <\/b>J. Pichler, Kepler University Hospital, Linz, <span class=\"xn-location\">Austria<\/span><br \/><b>Abstract #: <\/b>OP-778<\/p>\n<p><b>Title:<\/b>\u00a0Safety of radioligand therapy with <sup>177<\/sup>Lu-FAPi-Dimer (TLX400) with dose escalation in a clinical setting<sup>6<br \/><\/sup><b>Date and Time:<\/b> 8-Oct-25, 08:10 \u2013 08:20<br \/><b>Presenter: <\/b>J. <span class=\"xn-person\">Urena Poch<\/span>, Rostock University Medical Center, Rostock, <span class=\"xn-location\">Germany<\/span><br \/><b>Abstract #: <\/b>OP-779<\/p>\n<p><b>Title:<\/b>\u00a0Immunomodulation of the tumor microenvironment by <sup>225<\/sup>Ac-DOTA-girentuximab (TLX252) in a syngeneic murine tumor mode<br \/><b>Date and Time:<\/b> 8-Oct-25, 09:10 \u2013 09:20<br \/><b>Presenter: <\/b>R. Ladjohounlou, <span class=\"xn-org\">University of Wisconsin, Madison<\/span>, WI, U.S.<br \/><b>Abstract #: <\/b>OP-767<\/p>\n<p><b><u>Poster presentations<\/u><\/b><\/p>\n<p><b>Title:<\/b>\u00a0Preclinical development of <sup>161<\/sup>Tb-DOTA-HYNIC-panPSMA and comparison with <sup>177<\/sup>Lu-DOTA-HYNIC-panPSMA, <sup>161<\/sup>Tb-DOTA-J591 and <sup>177<\/sup>Lu-DOTA-J591 (TLX591)<br \/><b>Presenter: <\/b>C. Morgat, CHU Bordeaux, <span class=\"xn-location\">Bordeaux, France<\/span><br \/><b>Abstract #: <\/b>EP-0069<\/p>\n<p><b>Title:<\/b>\u00a0CAIX-targeting for radioimmunotherapy in triple-negative breast cancer<br \/><b>Presenter: <\/b>A. Ivashkevich, Telix Pharmaceuticals, <span class=\"xn-location\">Melbourne, Australia<\/span><br \/><b>Abstract #: <\/b>EP-0130<\/p>\n<p><b>Title:<\/b>\u00a0Prostate cancer detection with <sup><span class=\"xn-money\">99m<\/span><\/sup>Tc-HYNIC-iPSMA SPECT: The Australian experience<br \/><b>Presenter: <\/b>P. Tually, Spartan First Imaging, Kalgoorlie, <span class=\"xn-location\">Australia<\/span><br \/><b>Abstract #: <\/b>EP-0353<\/p>\n<p><b>Title:<\/b>\u00a0Potential of <sup>89<\/sup>Zr-girentuximab (TLX250-CDx) PET\/CT for the routine clinical management of patients with suspicious, unspecified renal lesions (real-world experience)<br \/><b>Presenter: <\/b>S. Rasul, Medical University of <span class=\"xn-location\">Vienna<\/span>, <span class=\"xn-location\">Vienna, Austria<\/span><br \/><b>Abstract #: <\/b>EP-0528<\/p>\n<p><b>Title:<\/b>\u00a0Improving clinical management of von Hippel-Lindau Syndrome with <sup>89<\/sup>Zr-girentuximab (TLX250-CDx) PET Imaging (real-world experience)<br \/><b>Presenter: <\/b>F. Gelardi, IRCCS Ospedale San Raffaele, <span class=\"xn-location\">Milan, Italy<\/span><br \/><b>Abstract #: <\/b>EP-0534<\/p>\n<p><b>Title:<\/b>\u00a0IPAX-2: Phase 1 safety and dose finding study of <sup>131<\/sup>I-IPA (TLX101) plus standard of care in patients with newly diagnosed glioblastoma<br \/><b>Presenter: <\/b>J. Pichler, Kepler University Hospital, Linz, <span class=\"xn-location\">Austria<\/span><br \/><b>Abstract #: <\/b>EP-0785<\/p>\n<p><b>Title:<\/b>\u00a0<sup>177<\/sup>Lu-DOTA-HYNIC-panPSMA radioligand therapy for patients with metastatic castration-resistant prostate cancer<br \/><b>Presenter: <\/b>Y. Omar, Misr Radiology Center, <span class=\"xn-location\">Cairo, Egypt<\/span><br \/><b>Abstract #: <\/b>EP-0810<\/p>\n<p><b>Title:<\/b>\u00a0Robust self-supervised deep learning reconstruction model for reduced <sup>89<\/sup>Zr-girentuximab (TLX250-CDx) PET scan time<br \/><b>Presenter: <\/b>C. Pain, Monash Biomedical Imaging, <span class=\"xn-location\">Melbourne, Australia<\/span><br \/><b>Abstract #: <\/b>EP-0978<\/p>\n<p><b>Title: <\/b>Preclinical evaluation of DOTAGA.PEG<sub>2<\/sub>.Glu.(FAPI)<sub>2<\/sub>, a FAP dimeric inhibitor, for developing theranostic radiotracers in FAP-positive malignancies<sup>6<br \/><\/sup><b>Presenter:<\/b> N. Kumar,\u00a0Bern University Hospital, <span class=\"xn-location\">Bern, Switzerland<\/span><br \/><b>Abstract #: <\/b>EPS-013<\/p>\n<p><b>Title:<\/b>\u00a0Intraindividual tumor dosimetry of monomer <sup>90<\/sup>Y-FAPI-46 vs dimer <sup>90<\/sup>Y-DOTAGA-Glu-(FAPI)<sub>2<\/sub> FAP radioligand therapy of advanced stage solid tumors<br \/><b>Presenter: <\/b>P. <span class=\"xn-person\">Fragoso Costa<\/span>, University Hospital Essen, University Duisburg-Essen, <span class=\"xn-location\">Essen, Germany<\/span><br \/><b>Abstract #: <\/b>EPS-190<\/p>\n<p><b>Title:<\/b>\u00a0Therapeutic potential of DOTAGA.Glu.(FAPI)<sub>2<\/sub> (TLX400) and DO3A.Glu.(FAPI)<sub>2<\/sub> with human dosimetry extrapolation for 177-lutetium and 161-terbium<sup>6<br \/><\/sup><b>Presenter: <\/b>A. Bilinska, Bern University Hospital, <span class=\"xn-location\">Bern, Switzerland<\/span><br \/><b>Abstract #: <\/b>EPS-193<\/p>\n<p><b><u>Rhine Pharma presentations<\/u><\/b><\/p>\n<p><b>Title:<\/b>\u00a0Impact of formulation buffers on the radiolysis and stability of RHN001-Tx (<sup>188<\/sup>Re-PSMA)<br \/><b>Date and Time:<\/b> 6-Oct-25, 10:45 \u2013 10:55<br \/><b>Presenter: <\/b>S. Mdanda, Nuclear Medicine Research Infrastructure (NuMeRI), <span class=\"xn-location\">Pretoria, South Africa<\/span> <br \/><b>Abstract #: <\/b>OP-349<\/p>\n<p><b>Title:<\/b>\u00a0Clinical trial protocol for RHINO trial: Prospective single-center Phase 1\/2 study of RHN001-Dx\/Tx in men with PSMA-positive prostate cancer post adjuvant androgen deprivation therapy and\/or taxane-based chemotherapy<br \/><b>Date and Time:<\/b> 8-Oct-25, 09:20 \u2013 09:30<br \/><b>Presenter: <\/b>H. Ndlovu, NuMeRI, <span class=\"xn-location\">Pretoria, South Africa<\/span> <br \/><b>Abstract #: <\/b>OP-825<\/p>\n<p><b>Title:<\/b>\u00a0A comparative analysis of normal organ biodistribution and tumor uptake pattern of novel RHN001-Dx (<sup><span class=\"xn-money\">99m<\/span><\/sup>Tc-PSMA) in correlation with tumor burden and its implications for theranostic use<br \/><b>Date and Time:<\/b> 8-Oct-25, 11:05 \u2013 11:15<br \/><b>Presenter: <\/b>S. Martlbauer, University Hospital Dusseldorf, Heinrich-Heine-University Dusseldorf, <span class=\"xn-location\">Dusseldorf, Germany<\/span><br \/><b>Abstract #: <\/b>OP-881<\/p>\n<p><b>Title:<\/b>\u00a0A calibration workflow for accurate quantification of rhenium-188 in RHN001-Tx for theranostic applications<br \/><b>Presenter: <\/b>M. Qebetu, NuMeRI, <span class=\"xn-location\">Pretoria, South Africa<\/span><br \/><b>Abstract #: <\/b>EP-0942<\/p>\n<p><b>Title:<\/b>\u00a0Quantitative <sup><span class=\"xn-money\">99m<\/span><\/sup>Tc-SPECT\/CT dosimetry using a CZT gamma camera: Initial clinical experience<br \/><b>Presenter: <\/b>K. Ramonaheng, NuMeRI, <span class=\"xn-location\">Pretoria, South Africa<\/span> <br \/><b>Abstract #: <\/b>EP-1116<\/p>\n<p><b>Title:<\/b>\u00a0Production optimization and quality control testing of RHN001-Tx (<sup>188<\/sup>Re-PSMA) per GMP standards<br \/><b>Presenter: <\/b>S. Sibiya, NuMeRI, <span class=\"xn-location\">Pretoria, South Africa<\/span> <br \/><b>Abstract #: <\/b>EP-1200<\/p>\n<div>\n<table border=\"0\" cellspacing=\"0\" cellpadding=\"1\" class=\"prnbcc\">\n<tbody>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">[1] Metastatic castration-resistant prostate cancer.<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">[2]\u00a0Clear cell renal cell carcinoma.<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">[3]\u00a0Carbonic anhydrase IX.<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">[4]\u00a0Fibroblast activation protein.<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">[5]\u00a0Imaging of prostate specific membrane antigen.<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">[6]\u00a0Presentation includes information about a Telix-owned or licensed FAP-targeting theranostic candidate without input or support from Telix.<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>\u00a0<\/p>\n<p><b>About <\/b><b>Rhine Pharma<\/b><\/p>\n<p>Rhine Pharma\u2122 is a wholly-owned subsidiary of Telix. Its mission is to expand global access to innovative cancer imaging and therapy by leveraging the unique benefits of technetium-99m (<sup><span class=\"xn-money\">99m<\/span><\/sup>Tc) and rhenium-188 (<sup>188<\/sup>Re).\u00a0 Visit <a href=\"http:\/\/www.rhine-pharma.com\/\" target=\"_blank\" rel=\"nofollow\">www.rhine-pharma.com<\/a>\u00a0for further information.<\/p>\n<p><b>About <\/b><b>Telix Pharmaceuticals Limited <\/b><\/p>\n<p>Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in <span class=\"xn-location\">Melbourne, Australia<\/span>, with international operations in <span class=\"xn-location\">the United States<\/span>, <span class=\"xn-location\">United Kingdom<\/span>, <span class=\"xn-location\">Brazil<\/span>, <span class=\"xn-location\">Canada<\/span>, <span class=\"xn-location\">Europe<\/span> (<span class=\"xn-location\">Belgium<\/span> and <span class=\"xn-location\">Switzerland<\/span>), and <span class=\"xn-location\">Japan<\/span>. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).<\/p>\n<p>Illuccix\u00ae (kit for the preparation of gallium-68 (<sup>68<\/sup>Ga) gozetotide injection), Telix&#8217;s first generation PSMA-PET imaging agent, has been approved in multiple markets globally. Gozellix\u00ae (kit for the preparation of gallium-68 (<sup>68<\/sup>Ga) gozetotide injection) has been approved by the U.S. Food and Drug Administration (FDA). Telix&#8217;s osteomyelitis (bone infection) imaging agent, technetium-99m (<sup><span class=\"xn-money\">99m<\/span><\/sup>Tc) besilesomab, marketed under the brand name Scintimun\u00ae, is approved in 32 European countries and <span class=\"xn-location\">Mexico<\/span>. Telix&#8217;s SENSEI\u00ae drop-in gamma probe is registered with the Australian Therapeutic Goods Administration (TGA) and with the FDA and has attained a Conformit\u00e9 Europ\u00e9enne (CE) Mark for use in the European Economic Area. Telix&#8217;s QDOSE\u00ae dosimetry software has received 510(k) clearance from the FDA and is CE-marked and Medical Device Regulation (MDR) certified for clinical use within the European Union (EU). No other Telix product has received a marketing authorization in any jurisdiction.<\/p>\n<p>Visit <a href=\"http:\/\/www.telixpharma.com\/\" target=\"_blank\" rel=\"nofollow\">www.telixpharma.com<\/a> for further information about Telix, including details of the latest share price, announcements made to the ASX, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on <a href=\"https:\/\/x.com\/TelixPharma\" target=\"_blank\" rel=\"nofollow\">X<\/a>\u00a0and\u00a0<a href=\"https:\/\/www.linkedin.com\/company\/telixpharma\/\" target=\"_blank\" rel=\"nofollow\">LinkedIn<\/a>.<\/p>\n<p><b>Telix Investor Relations<\/b><\/p>\n<p>Ms. Kyahn Williamson<br \/>Telix Pharmaceuticals Limited<br \/>SVP Investor Relations and Corporate Communications<br \/>Email: <a href=\"mailto:kyahn.williamson@telixpharma.com\" target=\"_blank\" rel=\"nofollow\">kyahn.williamson@telixpharma.com<\/a><\/p>\n<p><b>Legal Notices<\/b>\u00a0<\/p>\n<p>Cautionary Statement Regarding Forward-Looking Statements\u00a0\u00a0<\/p>\n<p><i>You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.\u00a0<\/i>\u00a0<\/p>\n<p><i>The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including <span class=\"xn-location\">the United States<\/span>. The information and opinions contained in this announcement are subject to change without notification. \u202fTo the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.\u00a0<\/i>\u00a0<\/p>\n<p><i>This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as &#8220;may&#8221;, &#8220;expect&#8221;, &#8220;intend&#8221;, &#8220;plan&#8221;, &#8220;estimate&#8221;, &#8220;anticipate&#8221;, &#8220;believe&#8221;, &#8220;outlook&#8221;, &#8220;forecast&#8221; and &#8220;guidance&#8221;, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix&#8217;s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix&#8217;s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix&#8217;s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix&#8217;s preclinical and clinical trials, and Telix&#8217;s research and development programs; Telix&#8217;s ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix&#8217;s product candidates, manufacturing activities and product marketing activities; Telix&#8217;s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix&#8217;s product candidates, if or when they have been approved; Telix&#8217;s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix&#8217;s expenses, future revenues and capital requirements; Telix&#8217;s financial performance; developments relating to Telix&#8217;s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix&#8217;s business; and the pricing and reimbursement of Telix&#8217;s product candidates, if and after they have been approved. Telix&#8217;s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.\u00a0<\/i>\u00a0<\/p>\n<p>Trademarks and Trade Names<\/p>\n<p><i>All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the \u00ae or \u2122 symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.\u00a0<\/i>\u00a0<\/p>\n<p><i>\u00a92025 Telix Pharmaceuticals Limited. All rights reserved.<\/i><\/p>\n<p><!-- \/wp:html --><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-35432","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/35432","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=35432"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/35432\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=35432"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=35432"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=35432"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}